NeoGenomics Gestione
Criteri Gestione verificati 1/4
NeoGenomics Il CEO è Tony Zook, nominato in Apr2025, e ha un mandato di 2.83 anni. la retribuzione annua totale è $ 9.35M, composta da 6.4% di stipendio e 93.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.12% delle azioni della società, per un valore di $ 1.37M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.1 anni e 5.3 anni.
Informazioni chiave
Tony Zook
Amministratore delegato
US$9.3m
Compenso totale
| Percentuale dello stipendio del CEO | 6.43% |
| Mandato del CEO | 1yr |
| Proprietà del CEO | 0.1% |
| Durata media del management | 1.1yrs |
| Durata media del Consiglio di amministrazione | 5.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
NEO: Medicare Test Coverage Will Support Bullish Repricing Through 2026 Guidance
Analysts have trimmed their price target on NeoGenomics from about $14.81 to roughly $14.19, citing updated assumptions for fair value, revenue growth, profit margin and future P/E that modestly reset expectations while keeping the broader thesis intact. What's in the News PanTracer LBx received coverage from the Centers for Medicare & Medicaid Services’ MolDX program under LCD L38043.
NEO: Expanded Genomic Test Coverage Will Support Stronger Outlook For 2026
Analysts have raised their price target on NeoGenomics from $12.00 to $13.00, citing updated assumptions for growth, profitability, discount rate, and a higher future P/E multiple. What's in the News PanTracer LBx liquid biopsy test received coverage from the Centers for Medicare & Medicaid Services’ MolDX program under LCD L38043, expanding access for Medicare patients to blood based comprehensive genomic profiling across more than 500 genes with a seven day turnaround (Key Developments).NEO: New Medicare Coverage Will Drive Bullish Repricing Through 2026 Guidance
Analysts have kept their $14.81 price target for NeoGenomics unchanged, citing stable modeled revenue growth, profit margins, and future P/E assumptions as the basis for maintaining their view. What's in the News Medicare, through the MolDX program, granted coverage for NeoGenomics' PanTracer LBx liquid biopsy test for plasma based genomic profiling in solid tumors, expanding access for Medicare patients to a blood based comprehensive genomic profiling assay that evaluates more than 500 genes with a seven day turnaround (Key Developments).NEO: Legal Victory And 2025–2026 Guidance Will Drive Bullish Repricing
Analysts have raised their price target on NeoGenomics from about $14.43 to roughly $14.81, citing updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News NeoGenomics launched RaDaR ST, a circulating tumor DNA assay for molecular residual disease that uses patient specific, tumor informed panels and whole exome sequencing to track up to 48 tumor variants with an LOD95 of 11 ppm.
NEO: Liquid Biopsy Expansion And Legal Win Will Support Long Term Upside
Analysts have kept their $17.00 price target for NeoGenomics unchanged, reflecting only small model tweaks to the discount rate, revenue growth assumptions, profit margin expectations, and future P/E that do not materially alter their overall view of the stock. What's in the News Issued earnings guidance for 2026 with expected consolidated revenue of US$793 million to US$801 million and a projected net loss of US$63 million to US$50 million.NEO: Fair Outlook Balances Leadership Transition Patent Win And Clinical Data
Narrative Update on NeoGenomics Analysts have lifted their implied fair value estimate for NeoGenomics to US$12.00 per share, citing updated assumptions around revenue growth, discount rate, profit margin and future P/E as the key drivers behind the new price target framework. What’s in the News NeoGenomics announced a CFO succession plan, with Abhishek Jain joining as Executive Vice President on January 12, 2026 and scheduled to become CFO on March 2, 2026, as current CFO Jeff Sherman transitions toward retirement on April 14, 2026, after completing the fiscal 2025 reporting cycle.NeoGenomics: Distribution Moat In Community Oncology
Jan 25NEO: Legal Win And 2025 Guidance Will Drive Bullish Repricing
Analysts have raised their price target for NeoGenomics to about US$14.43 from roughly US$13.44, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that refine their view of the company’s long-term earnings power. What's in the News Issued preliminary unaudited guidance for the fourth quarter of 2025 with expected total revenue of about US$190 million and year over year growth of 11%, and full year 2025 revenue of about US$727 million with year over year growth of 10% (company guidance).NEO: Future Liquid Biopsy Data Pipeline Will Support Stronger Long Term Outlook
Analysts have lifted their fair value estimate for NeoGenomics from US$14.00 to US$17.00. They cite updated assumptions around revenue growth, profit margins and future P/E that they believe better reflect the company’s outlook.NEO: Upcoming Trial Readouts And Guidance Will Drive Bullish Repricing
Narrative Update on NeoGenomics Analysts have modestly raised their price target on NeoGenomics to approximately 13.44 dollars from about 13.17 dollars, citing slightly stronger long term revenue growth expectations and a marginally higher future earnings multiple, despite a nearly unchanged discount rate and profit margin outlook. What's in the News Upcoming SABCS 2025 presentations will showcase RaDaR 1.0 ctDNA data from the SURVIVE HERoes Phase III trial and CLEVER study in early breast cancer, supporting ctDNA guided surveillance and earlier intervention strategies (company announcement).NEO: Upcoming Research and Earnings Guidance Will Shape Market Expectations
Analysts have slightly raised their price target for NeoGenomics from $13.06 to $13.17 per share. This reflects updated assessments of future profitability and market growth potential.NEO: Upcoming Research Presentations Are Expected To Drive Solid Tumor Detection Momentum
Analysts have raised their fair value estimate for NeoGenomics from $11.72 to $13.06. This change is attributed to slightly improved revenue growth projections, as well as a modest increase in profit margins and future valuation multiples.NEO: Upcoming Research Presentations Will Accelerate Future Oncology Diagnostic Opportunities
Analysts have raised their price target for NeoGenomics from $10.44 to $11.72 per share. They cite marginal improvements in projected revenue growth and profit margin estimates.Advanced Oncology Diagnostics And NGS Capabilities Will Create Future Opportunities
Analysts have raised their price target for NeoGenomics from $9.78 to $10.44 per share, citing slightly improved revenue growth projections and a modestly higher future price-to-earnings multiple. What's in the News NeoGenomics announced the presentation of key MRD assay data, including results from interventional therapy trials, at the upcoming ESMO Congress 2025 in Berlin.Advanced Oncology Diagnostics And NGS Capabilities Will Create Future Opportunities
The higher analyst price target for NeoGenomics reflects an expansion in its future P/E multiple despite stable revenue growth forecasts, resulting in a revised fair value of $9.78. What's in the News U.S. District Court invalidated certain Natera patents asserted against NeoGenomics’ RaDaR v1.1 test, but the decision does not affect the '035 patent that previously led to a permanent injunction on RaDaR v1.0. NeoGenomics launched NEO PanTracer LBx, a blood-based comprehensive genomic profiling (CGP) test targeting the expanding liquid biopsy market and enhancing its pan-solid tumor CGP portfolio.Would NeoGenomics (NASDAQ:NEO) Be Better Off With Less Debt?
Aug 27
Market Cool On NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues Pushing Shares 27% Lower
Jul 30Take Care Before Jumping Onto NeoGenomics, Inc. (NASDAQ:NEO) Even Though It's 25% Cheaper
May 23
PanTracer Launch And MRD Collaboration Will Strengthen Future Cancer Testing Leadership
NeoGenomics' strategic investments and collaborations are expected to enhance customer experiences, boost test volumes, and strengthen competitive positioning in MRD monitoring and Heme testing.NeoGenomics, Inc.'s (NASDAQ:NEO) Stock Retreats 28% But Revenues Haven't Escaped The Attention Of Investors
Mar 08NeoGenomics: Decent Fundamentals, But Still Overvalued
Feb 28Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt
Feb 18What You Can Learn From NeoGenomics, Inc.'s (NASDAQ:NEO) P/S After Its 29% Share Price Crash
Jan 14NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable
Nov 23Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Oct 16Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%
Aug 01Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Jul 15Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$99m |
| Dec 31 2025 | US$9m | US$602k | -US$108m |
| Sep 30 2025 | n/a | n/a | -US$113m |
| Jun 30 2025 | n/a | n/a | -US$104m |
| Mar 31 2025 | n/a | n/a | -US$78m |
| Dec 31 2024 | US$320k | n/a | -US$79m |
| Sep 30 2024 | n/a | n/a | -US$78m |
| Jun 30 2024 | n/a | n/a | -US$79m |
| Mar 31 2024 | n/a | n/a | -US$84m |
| Dec 31 2023 | US$276k | n/a | -US$88m |
Compensazione vs Mercato: La retribuzione totale di Tony ($USD 9.35M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.70M ).
Compensazione vs guadagni: La retribuzione di Tony è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Tony Zook (64 yo)
1yr
Mandato
US$9,348,604
Compensazione
Mr. Anthony P. Zook, also known as Tony, serves as an Independent Director at Adaptin Bio Operating Corporation since February 2025. He is CEO of NeoGenomics, Inc. from April 1, 2025 and has been its Direc...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 1yr | US$9.35m | 0.12% $ 1.4m | |
| President & COO | 1yr | US$5.07m | 0.12% $ 1.4m | |
| Chief Digital & Information Officer | 1.3yrs | US$278.63k | 0.018% $ 212.8k | |
| Executive VP of Business Development | 4yrs | US$3.05m | 0.072% $ 840.9k | |
| Chief People & Culture Officer | no data | US$2.44m | 0.060% $ 707.3k | |
| Executive VP & CFO | less than a year | Nessun dato | Nessun dato | |
| Senior VP & Chief Accounting Officer | 2.9yrs | Nessun dato | 0.017% $ 198.7k | |
| Vice President of Investor Relations & Communications | no data | Nessun dato | Nessun dato | |
| Vice President of Compliance & Privacy | less than a year | Nessun dato | Nessun dato | |
| Head of Strategy | 2.3yrs | Nessun dato | Nessun dato | |
| Chief Innovation Officer | no data | Nessun dato | Nessun dato | |
| Senior Vice President of Finance | no data | Nessun dato | Nessun dato |
1.1yrs
Durata media
50.5yo
Età media
Gestione esperta: Il team dirigenziale di NEO non è considerato esperto (durata media 1.1 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 2.8yrs | US$9.35m | 0.12% $ 1.4m | |
| Independent Director | 5.8yrs | US$319.68k | 0.034% $ 397.0k | |
| Independent Director | 3.4yrs | US$319.30k | 0.026% $ 305.7k | |
| Independent Chair of the Board | 10.8yrs | US$365.15k | 0.057% $ 664.3k | |
| Member of Scientific Advisory Board | 5.3yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 5.3yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 5.3yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 5.3yrs | Nessun dato | Nessun dato | |
| Independent Director | 8.8yrs | US$302.92k | 0.040% $ 472.1k | |
| Member of Scientific Advisory Board | 5.3yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 5.3yrs | US$418.58k | 0.10% $ 1.2m | |
| Member of Scientific Advisory Board | 5.3yrs | Nessun dato | Nessun dato |
5.3yrs
Durata media
65yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di NEO sono considerati esperti (durata media dell'incarico 5.3 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/04/29 20:11 |
| Prezzo dell'azione a fine giornata | 2026/04/29 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
NeoGenomics, Inc. è coperta da 25 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Bruce Jackson | Benchmark Company |
| Raymond Myers | Benchmark Company |
| Michael Ryskin | BofA Global Research |